NUWE News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

NU

Mkt Cap

$1.7M

Volume

104.72K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility MedicalNuwellis announced a co-promotion and distribution agreement with Atrility Medical for the AtriAmp device, an FDA-cleared technology for temporary epicardial pacing. The deal includes an initial six-month pilot across nine Western and five Southeastern states, with a pathway to exclusive U.S. distribution upon successful completion. This strategic partnership allows Nuwellis to expand its pediatric and critical care portfolio without significant additional infrastructure investment.GlobeNewswire Inc. · Aug 25, 2026

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNuwellis (NUWE) announced a $3.4 million registered direct offering of 1,310,890 shares at $2.59 per share, along with $3.1 million in warrant exercise proceeds from its June 2026 public offering. The company will also issue concurrent warrants to investors with a five-year term. The offering is expected to close on August 3, 2026.GlobeNewswire Inc. · Jul 31, 2026

Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)Nuwellis, Inc. (Nasdaq: NUWE) marks five years of supporting the Pediatric Cardiac Critical Care Consortium (PC4) annual conference, collaborating with leading pediatric cardiac institutions to advance fluid management education and awareness. The company's Aquadex SmartFlow system is utilized across major pediatric cardiac centers for managing fluid overload in critically ill children. Incoming CEO Mike McCormick emphasized the company's commitment to pediatric care advancement and fluid management strategies in cardiac ICUs.GlobeNewswire Inc. · Jun 26, 2026

Nuwellis Announces Closing of $6.0 Million Registered Public OfferingNuwellis (NASDAQ: NUWE), a medical technology company focused on cardiorenal conditions, announced the successful closing of a $6.0 million registered public offering. The offering included 1.9 million shares of common stock and pre-funded warrants, with accompanying Series C and D warrants. The public offering price was $0.30 per share with accompanying warrants.Benzinga · Jun 9, 2026

Nuwellis Announces Closing of $6.0 Million Registered Public OfferingNuwellis, Inc. (Nasdaq: NUWE) announced the successful closing of a public offering raising approximately $6.0 million through the sale of 1,903,338 shares of common stock and pre-funded warrants, along with Series C and D warrants. The offering was priced at $0.30 per share with accompanying warrants. Ladenburg Thalmann & Co. Inc. served as the sole book-running manager.GlobeNewswire Inc. · Jun 9, 2026

Nuwellis, Inc. Announces First Quarter 2026 Financial ResultsNuwellis, Inc. (NUWE) reported Q1 2026 net sales of $2.4 million, up 26% year-over-year, with gross margin improving to 70.1%. The company completed the Rendiatech acquisition, appointed new CFO and board members, and expanded commercial coverage. However, the company posted a net loss of $4.3 million and held only $2.2 million in cash with no debt.GlobeNewswire Inc. · May 12, 2026

Nuwellis Completes Acquisition of RendiatechNuwellis (NASDAQ: NUWE) has completed its acquisition of Rendiatech, an Israeli developer of automated kidney function monitoring technology. The acquisition expands Nuwellis' capabilities in fluid management and kidney function monitoring, complementing its existing Aquadex SmartFlow System. The technology enables continuous renal monitoring with real-time data capture to support clinical decision-making in critically ill patients.Benzinga · Mar 17, 2026

Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio StrategyNuwellis (NASDAQ: NUWE) announced a definitive agreement to acquire Rendiatech Ltd., an Israeli medical technology company specializing in automated kidney function monitoring. The acquisition expands Nuwellis' cardiorenal portfolio beyond therapeutic fluid management into real-time renal diagnostics, leveraging Rendiatech's Clarity system for continuous urine-output measurement. The transaction is expected to close following customary conditions and will be integrated using Nuwellis' existing commercial infrastructure.Benzinga · Jan 29, 2026

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring CompanyNuwellis has signed a non-binding letter of intent to acquire Rendiatech, an Israeli medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies, potentially expanding its fluid management technology platform.Benzinga · Aug 19, 2025

Nuwellis Stockholders Approve All Proposals at Special MeetingNuwellis held a Special Meeting of Stockholders, where shareholders approved proposals to increase authorized shares, potentially conduct a reverse stock split, and issue shares from a recent financing to enhance financial flexibility.GlobeNewswire Inc. · Aug 4, 2025

NU

NUWENuwellis, Inc. Common Stock

NUWE

Pay with—

Available Balance0.00

Your PositionYou don't own any NUWE yet.

Related Tickers

Earnings